Targeting Vaccines to Dendritic Cells
- 1 January 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 19 (3), 229-238
- https://doi.org/10.1023/a:1014474414097
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Will the Making of Plasmacytoid Dendritic Cells in Vitro Help Unravel Their Mysteries?The Journal of Experimental Medicine, 2000
- Consequences of Cell DeathThe Journal of Experimental Medicine, 2000
- The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cellsEuropean Journal of Immunology, 1997
- Effect of interleukin‐10 on dendritic cell maturation and functionEuropean Journal of Immunology, 1997
- The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-LigandThe Journal of Experimental Medicine, 1997
- Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term CulturesThe Journal of Experimental Medicine, 1997
- Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.The Journal of Experimental Medicine, 1995
- The endocytic activity of dendritic cells.The Journal of Experimental Medicine, 1995
- Uptake of microparticle‐adsorbed protein antigen by bone marrow‐derived dendritic cells results in up‐regulation of interleukin‐1α and interleukin‐12 p40/p35 and triggers prolonged, efficient antigen presentationEuropean Journal of Immunology, 1995
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994